Микроальбуминурия - диагностическое и прогностическое значение при артериальной гипертонии

артериальная гипертония, микроальбуминурия, нефропатия, прогрессирование, ренопротекция

1. Мухин Н.А., Арутюнов Г.П., Фомин В.В. Альбуминурия - маркер поражения почек и риска сердечно-сосудистых осложнений // Клинич. Нефрология. - 2009. - № 1. - С. 5-10.

2.

3. Семидоцкая Ж.Д., Оспанова Т.С., Бездетко Т.В. и др. Микроальбуминурия - предиктор и маркер нефропатии // Вестн. ХНМУ. - 2008. - Т. 12, № 1. - С. 221-222.

4.

5. Bennet P.H., Haffne S., Kasiske B.L. et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the Kidney Foundation from an ad hoc committee of the Council of Diabetes Mellitus of the National Kidney Foundation // Am. J. Kidney Dis. - 1995. - Vol. 25, № 1. - Р. 107-112.

6.

7. Garg A.X., Kiberd B.A., Clark W.F. et al. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III // Kidney Int. - 2002. - Vol. 61, № 6. - Р. 2165-2175.

8.

9. Jones C.A., Francis M.E., Eberhardt M.S. et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey // Am. J. Kidney Dis. - 2002. - Vol. 39, № 3. - Р. 445-459.

10.

11. Преображенский Д.В., Маревич А.В., Романова Н.Е. и др. Микроальбуминурия: диагностическое, клиническое и прогностическое значение // Рос. кардиол. журн. - 2000. - № 3. - С. 79-86.

12.

13. Pontremolli R., Nicolella R., Viazzi F. et al. Microalbuminuria is an early marker of target organ damage in essential hypertension // Am. J. Hypertens. - 1998. - Vol. 11, № 4, Pt. 1. - Р. 430-438.

14.

15. Дедов И.И., Шестакова М.В. Диабетическая нефропатия. - Москва: Универсум Паблишинг, 2000. - 239 c.

16.

17. Knight E.L., Kramer H.M., Curhan G.C. High-normal blood pressure and microalbuminuria // Am. J. Kidney Dis. - 2003. -Vol. 41, № 3. - Р. 588-595

18.

19. Cirillo M., Stellato D., Laurenzi M. et al. Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group // Kidney Int. - 2000. - Vol. 58, № 3, suppl. 3. - Р. 1211-1218.

20.

21. Лепаева Т.В., Длин В.В., Казанская И.В. и др. Микроальбуминурия при рефлюкс-нефопатии у детей // Нефрология и диализ. - 2009. - № 1. - С. 31-34.

22.

23. de Ferranti S., Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions // Clin. Chem. Acta. - 2002. - Vol. 317, № 1-2. - P. 1-15.

24.

25. Nakamura M., Onoda T., Itai K. et al. Association between serum C-reactive protein levels and microalbuminuria: a population based cross sectional studying northern Iwate, Japan // Intern. Med. - 2004. - Vol. 43, № 10. - Р. 919-925.

26.

27. Stuveling E.M., Hillege H.L., Bakker J.L. et al. C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease // Atherosclerosis. - 2004. - Vol. 172, № 1. - Р. 107-114.

28.

29. Tsioufis C., Dimitriadis K., Chatzis D. et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension // Am. J. Cardiol. - 2005. - Vol. 96, № 7. - Р. 946-951.

30.

31. Pedrinelli R., Penno G., Pucci L. et al. Inflammatory microalbuminuria, metabolic abnormalities and cardiovascular risk in non-diabetic hypertensive men // Hypertension. - 2004. - Vol. 22 (suppl. 2). - P. 95.

32.

33. Diercks G.F., Janssen W.M., van Boven A.J. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]) // Am. J. Cardiol. - 2000. - Vol. 86, № 6. - Р. 635-638.

34.

35. Pedrinelli R., Dell'Omo G., Di Bello V. et al. Low-grade inflammation and microalbuminuria in hypertension // Arterioscler. Thromb. Vasc. Biol. - 2004. - Vol. 24, № 12. - Р. 2414-2419.

36.

37. Grunfeid В., Perelstein E., Simolo B. et al. Renal function reserve and microalbuminuria in offsprings of hypertensive patients // Hypertension. - 1990. - Vol. 15, № 3. - Р. 257-261.

38.

39. Pontremoli R., Sofia A., Tirotta A. et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension // J. Am. Soc. Nephrol. - 1996. -Vol. 7, № 12. - Р. 2550-2558.

40.

41. Минушкина Л.О., Бражник В.А., Носиков В.В., Затейщиков Д.А. Генетические аспекты развития микроальбуминурии у больных гипертонической болезнью // Кардиология. - 2008. - № 11. - С. 29-35.

42.

43. Young R.P., Chan J.C., Critchley J.A. et al. Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients // Diabetes Care. - 1998. - Vol. 21, № 3. - Р. 431-437.

44.

45. Valensi P., Assayag M., Busby M. et al. Microalbuminuria in obese patients with or without hypertension // Int. J. Obesity. - 1996. - Vol. 20, № 6. - Р. 574-579.

46.

47. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice // Int. J. Clin. Pract. - 2008. - Vol. 62, № 1. - Р. 97-108.

48.

49. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. - 1999. - Vol. 353, № 9153. - P. 611-616.

50.

51. Ohkubo T., Imai Y., Tsuji I. et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion. The Ohasama Study // Hypertension. - 1998. - № 32, № 2. - P. 255-259.

52.

53. Cirillo M., Senigalliesi L., Laurenzi M. et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study // Arch. Intern. Med. - 1998. - Vol. 158, № 17. - Р. 1933-1939.

54.

55. Иванов Д.Д. Микроальбуминурия: взгляд нефролога // Здоровье Украины. - 2008. - №21/1. - С. 18-19.

56.

57. Кобалава Ж.Д. Новое в лечении артериальной гипертоний // Практикующий врач. - 2001. - № 2. - С. 1-10.

58.

59. Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением // Терапевт. арх. - 2005. - № 5. - С. 36-41.

60.

61. Shankar S.S., Steinberg H.O. Obesity and endothelial dysfunction // Semin. Vasc. Med. - 2005. - Vol. 5, № 1. - Р. 56-64.

62.

63. Gunter W., Sheldon C., Han D.C. et al. Leptin and renal disease // Am. J. Kidney Dis. - 2002. - Vol. 39. - Р. 1-11.

64.

65. Baud L., Fouqueray B., Amrani P.C. Tumor necrosis factor alpha and mesangial cells // Kidney Int. - 1992. - Vol. 41, № 3.- Р. 600-603.

66.

67. Haffner S.M., Stem M.P., Gruber К.К. et al. Microalbuminuria. Potential marker for increased cardiovascular risk factors on nondiabetic subjects // Arteriosclerosis. - 1990. - Vol. 10, № 5. - Р. 727- 731.

68.

69. Borch-Johnsen K., Feldt- Rasmussen B., Strandgaard S. et al. Urinary albumin excretion. An independent predictor of ischemic heart disease // Arterioscler. Thomb. Vasc. Biol. - 1999. - Vol. 19, № 8. - Р. 1992-1997.

70.

71. Lekatsas I., Koulouris S., Triantafyllou K. et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction // Int. J. Cardiol. - 2006. - Vol. 106, № 2. - Р. 218-223.

72.

73. Szczudlik A., Turaj W., Slowik A., Strojny J. Microalbuminuria and hyperthermia independently predict long-term mortality in acute ischemic stroke patient // Acta. Neurol. Scand. - 2003.-Vol. 107, № 2.- Р. 96-101.

74.

75. Wachtell K., Ibsen H., Olsen M.H. et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study // Ann. Intern. Med. - 2003. - Vol. 139, № 11. - Р. 901-906.

76.

77. American Diabetes Association: Standards of medical care in diabetes - 2008. // Diabetes Care. - 2008. - Vol. 31, suppl. 1. - P. 12-54.

78.

79. Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency // N. Engl. J. Med. - 1996. - Vol. 334, № 15.- P. 939-945.

80.

81. Моисеев В.С. Ингибиторы АПФ и нефропатия // Клинич. фармакология и терапия. - 1997. - Т. 4, № 6. - С. 67-69.

82.

83. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases // Lancet. - 2001. - Vol. 357, № 9268. - P. 1601-1608.

84.

85. Сonzales R.F. et al. Duration of Trandolapril antihypertensive effects after 24 and 48 hours from the last dose THOR study // Clin. Drug Invest. - 1999. - Vol. 17, № 1. - Р. 43-50.

86.

87. Ruggenenti P., Fassi A., Ilieva A.P. et al. Preventing microalbuminuria in type 2 diabetes // N. Engl. J.Med. - 2004. - Vol. 351, № 19. - Р. 1941-1951.

88.

89. Bakris G., Weir M.R., DeQuattro V., McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy // Kidney Int. - 1998. - Vol . 54, № 4. - Р. 1283-1289.

90.

91. Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // Brit. Med. J. - 2000. - Vol. 321, № 7274. - Р. 1440-1444.

92.

93. Viberti G., Wheeldon N.M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect // Circulation. - 2002. - Vol. 106, № 6. - Р. 672-678.

94.

95. Marre М., Puig J.G., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study // J. Hypertens. - 2004. - Vol. 22, № 8. - Р. 1613-1622.

96.

97. Bakris G., Burgess E., Weir M. et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy // Kidney Int. - 2008. - Vol. 74, № 3. - Р. 364-369.

98.

99. Gerstein H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE // Diabetes Metab. Res. Rev. - 2002. - Vol. 18, suppl. 3. - Р. S82-85.

100.

101. Parving H.H., Persson F., Lewis J.B. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2008. - Vol. 358, № 23. - Р. 2433-2446.

102.